



HU000027012T2

(19) **HU****MAGYARORSZÁG**  
**Szellemi Tulajdon Nemzeti Hivatala**(11) Lajstromszám: **E 027 012**(13) **T2**

## EURÓPAI SZABADALOM

### SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 06 754502**(22) A bejelentés napja: **2006. 06. 22.**(51) Int. Cl.: **C07D 239/42** (2006.01)**A61K 315/05** (2006.01)

(96) Az európai bejelentés bejelentési száma:

**EP 20060754502**

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/EP 06/006008**

(97) Az európai bejelentés közzétételi adatai:

**EP 1915349 A2** **2006. 12. 28.**

(87) A nemzetközi közzétételi szám:

**WO 06136408**

(97) Az európai szabadalom megadásának meghirdetési adatai:

**EP 1915349 B1** **2015. 12. 09.**

(30) Elsőbbségi adatok:

**200500187** **2005. 06. 24.** **SI**

(73) Jogosult(ak):

**LEK Pharmaceuticals d.d., 1526 Ljubljana (SI)**

(72) Feltaláló(k):

**CASAR, Zdenko, 1370 Logatec (SI)****ZLICAR, Marko, 3000 Celje (SI)**

(74) Képviselő:

**SBGK Szabadalmi Ügyvivői Iroda, Budapest**

(54)

**Eljárás tiszta amorf rosuvasztatin kalcium előállítására**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19)



(11)

**EP 1 915 349 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:  
**09.12.2015 Bulletin 2015/50**

(21) Application number: **06754502.0**

(22) Date of filing: **22.06.2006**

(51) Int Cl.:  
**C07D 239/42 (2006.01) A61K 31/505 (2006.01)**

(86) International application number:  
**PCT/EP2006/006008**

(87) International publication number:  
**WO 2006/136408 (28.12.2006 Gazette 2006/52)**

(54) **PROCESS FOR PREPARING PURE AMORPHOUS ROSUVASTATIN CALCIUM**

VERFAHREN ZUR HERSTELLUNG VON REINEM AMORPHEN ROSUVASTATIN-CALCIUM

PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE CALCIQUE PURE AMORPHE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**

(30) Priority: **24.06.2005 SI 200500187**

(43) Date of publication of application:  
**30.04.2008 Bulletin 2008/18**

(73) Proprietor: **LEK Pharmaceuticals d.d.**  
**1526 Ljubljana (SI)**

(72) Inventors:  
• **CASAR, Zdenko**  
**1370 Logatec (SI)**  
• **ZLICAR, Marko**  
**3000 Celje (SI)**

(56) References cited:  
**EP-A1- 0 521 471 WO-A-00/49014**  
**WO-A-01/60804 WO-A-2005/040134**  
**WO-A-2005/077917 WO-A2-2005/023778**  
**WO-A2-2006/035277**

**EP 1 915 349 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****Field of the invention**

**[0001]** The present invention relates to a new process for preparing pure amorphous rosuvastatin calcium, substantially free of impurities.


**Background of the invention**

**[0002]** Rosuvastatin is generic name for (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid administered in the therapy as its calcium salt as commercial drug, and illustrated in Formula 1 hereinafter, which compound is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase), useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis. Rosuvastatin and the synthesis of rosuvastatin calcium was first disclosed in patent EP-B-521 471; in the last two steps of the whole synthesis provided by hydrolysis of methyl ester of rosuvastatin (methyl rosuvastatin) in polar solvent, e.g. ethanol, in the presence of a base, following by isolation of sodium salt of rosuvastatin (sodium rosuvastatinate) and converting said sodium salt of rosuvastatin with a water soluble calcium salt under aqueous conditions to calcium salt of rosuvastatin. The process for the preparation of the intermediates disclosed in EP-B-521 471 patent is incorporated herein by reference.

**[0003]** WO 2005/023778 discloses a process for the preparation of rosuvastatin calcium by conversion of C<sub>1</sub> to C<sub>4</sub> alkyl ester of rosuvastatin, preferably *tert*-butyl ester of rosuvastatin with a base, preferably sodium hydroxide, in the presence of a C<sub>1</sub> to C<sub>4</sub> alcohol, preferably ethanol, to a solution of rosuvastatin salt, e.g. its sodium salt and converted said salt into rosuvastatin calcium by adding a source of calcium to said solution.

**[0004]** A novel crystalline form of rosuvastatin calcium can be prepared by crystallization of amorphous form of rosuvastatin calcium from a mixture of: (i) water and acetonitrile in the ratio of 1 : 1 by volume; (ii) water and acetone in the ratio of 1 : 1 by volume; or water, methanol and *tert*-butyl methyl ether in the ratio of 1 : 1 : 1 by volume, what is described in WO 2000/042024.

**[0005]** WO 2005/040134 describes amorphous rosuvastatin calcium having a purity of more than 99% obtained from known crystalline rosuvastatin calcium. Said crystalline form may be prepared by crystallization of amorphous rosuvastatin calcium which process is known from the prior art.

**Formula 1**

**[0006]** It is well known that alkali metal salts of organic carboxylic acids are often hygroscopic what may cause problems at isolation. Indeed the isolation of sodium salt of rosuvastatin, which can be an intermediate in preparing rosuvastatin calcium salt, might be unrepeatable in yield and physical state what depends on the reaction conditions and evaporation of solvents, which is difficult to control. International publication WO 05/23778 tried to avoid said problems without isolating rosuvastatin sodium salt by extraction of impurities from its aqueous solution, but by using C<sub>1</sub> to C<sub>4</sub> alcohols as reaction medium a risk of conversion into specific impurities still existed. Namely, it is known that  $\beta$ -hydroxy acids in alcoholic alkali solution are submitted to dehydration what may lead after realkoxylation into special side products (see Scheme 1, wherein R and R<sub>1</sub> independently denotes C<sub>1</sub> to C<sub>6</sub> alkyl group), O-alkyl rosuvastatin, e.g. O-ethyl rosuvastatin.

**[0007]** Figure 1 shows results of stress stability test, from which is obvious that rosuvastatin was submitted to specific degradation in ethanol as alcoholic medium.

**[0008]** The specific impurity, designated as NN 20-47.143 is O-ethyl ether derivative (see Scheme 1 wherein R denotes ethyl (Et) group), was detected in 0.35% area by HPLC in comparison with acetone solution in which no such impurity was observed.

**[0009]** Therefore a need for an efficient process for preparing pure rosuvastatin calcium, without any significant amounts of side products, still exists.

### **Summary of the Invention**

**[0010]** The present invention provides a process for producing amorphous rosuvastatin calcium according to claim 1, alternatively according to claim 8.

**[0011]** Preferred embodiments are set forth in the subclaims to claim 1 and claim 8, respectively.

**[0012]** The present invention further provides process according to claim 16 or claim 17, and a pharmaceutical formulation according to claim 18.

**[0013]** The present invention allows a new more convenient procedure of preparing of monohydrates of rosuvastatin calcium.

**[0014]** Rosuvastatin calcium prepared by such improved procedures according to the invention has at least 99.5 % of chromatographic purity; moreover when using very pure starting C<sub>1</sub> to C<sub>5</sub> rosuvastatin ester of the invention more than 99.8 % purity, even more, in some cases more than 99.9 % of chromatographic purity of desired rosuvastatin calcium may be obtained.

**[0015]** The term "chromatographic purity" means purity as determined by HPLC ("High Pressure Liquid Chromatography").

**[0016]** The rosuvastatin calcium and the pharmaceutical formulation according to the present invention can be used for the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis. Treatment can comprise the step of administering the said pharmaceutical formulation to the mammal in need thereof.

**[0017]** The starting ester may be preferably methyl ester of rosuvastatin, more preferably *tert*-butyl ester of rosuvastatin (*tert*-butyl rosuvastatin).

**[0018]** As to the aprotic solvent of step a) of above described process reaction, preferably tetrahydrofuran (THF) or amide solvent (preferably *N,N*-dimethylacetamide (DMA)) is used.

**[0019]** The base used in the above described process of step a) is selected from the group consisting of sodium hydroxide, potassium hydroxide, and their analogues.

**[0020]** Any appropriate source of calcium source may be used, preferably calcium chloride or calcium acetate.

### **Detailed description of the Invention**

**[0021]** An object of the present invention is to find a novel process for the preparation of pure amorphous rosuvastatin calcium, substantially free of impurities, which would avoid the use of alcohols, e.g. C<sub>1</sub> to C<sub>4</sub> alcohol as a reaction medium known in the prior art processes, thus resulting to elimination O-alkyl rosuvastatin impurities (see Scheme 1), e.g. O-ethyl rosuvastatin, containing in rosuvastatin calcium, prepared according to the prior art processes.

**[0022]** Further is the object of the present invention to find a novel process which would enable easy and simple preparation and isolation of intermediary rosuvastatin salt, e.g. rosuvastatin sodium or rosuvastatin acid, in good quality, crystallinity and repeatedly, which were difficult to isolate in the prior art processes and which would enable simple and easy conversion of said intermediary compounds to desired commercial rosuvastatin calcium.

**[0023]** The term "substantially free of impurities" means less than 0.5% of total impurities as measured by area percentage HPLC, preferably less than 0.2% of total impurities as measured by area percentage HPLC, most preferably less than 0.1% of total impurities as measured by area percentage HPLC.

**[0024]** We have unexpectedly and surprisingly found that above problem has been solved by hydrolysis of starting C<sub>1</sub> to C<sub>6</sub> alkyl esters of rosuvastatin, where instead of using C<sub>1</sub> to C<sub>4</sub> alcohols as solvent medium known in the prior art processes said hydrolysis take place in an aprotic solvents, either tetrahydrofuran (THF), optionally with added water, or *N,N*-dimethylacetamide (DMA) and diethylether in the absence of water.

**[0025]** In the first embodiment of the invention a C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin, where alkyl denotes methyl, ethyl, n-propyl, *iso*-propyl, n-butyl, *iso*-butyl, *tert*-butyl, amyl and *tert*-amyl group, most preferably *tert*-butyl ester of rosuvastatin, is reacted with sodium hydroxide base in tetrahydrofuran (THF) containing medium, which may be in the mixture with other solvents, preferably THF and water mixture in all ratios, more preferably the mixture of tetrahydrofuran and water in the ratio of 5:1 to 1:5 by volume. Pure THF may be employed as medium as well. After completing of said hydrolysis reaction preferably rosuvastatin sodium is obtained. Hydrolysis of starting C<sub>1</sub> to C<sub>5</sub> ester of rosuvastatin may be performed at temperatures from 20°C to 60°C. The hydrolysis is accomplished in 30 minutes (at 60°C) to 2 hours (at 20°C).

Thereafter the obtained reaction mixture may be diluted with another solvent, preferably with water, if aqueous poor hydrolysis medium has been previously used. The aprotic organic solvent is then optionally removed, the residual aqueous solution is washed by water immiscible organic solvent selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably more user friendly solvents, e.g. acetate esters, more preferably ethyl acetate (AcOEt), or cyclic hydrocarbons, to obtain aqueous solution of pure rosuvastatin alkaline salt, preferably sodium salt of rosuvastatin.

**[0026]** Alternatively, after said hydrolysis in water rich media, the reaction mixture is washed by water immiscible organic solvents selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably selected from more user friendly solvents, e.g. acetate esters or cyclic hydrocarbons, more preferably ethyl acetate, without previous partial evaporation of organic component of the mixture with water, for example tetrahydrofuran.

**[0027]** Thereafter a source of calcium ions is added to the solution of rosuvastatin salt, preferably to the solution of rosuvastatin sodium salt, for instance calcium halogenide, preferably calcium chloride, and another calcium source, for example calcium nitrate or calcium hydroxide, calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid, preferably calcium palmitate, calcium pivalate or calcium acetate. The most preferable calcium source is calcium acetate monohydrate (Ca(OAc)<sub>2</sub>×H<sub>2</sub>O). Addition of Ca(OAc)<sub>2</sub>×H<sub>2</sub>O may be performed at temperatures between 0 °C to 40 °C. Ca(OAc)<sub>2</sub>×H<sub>2</sub>O may be added in one portion or dropwise in 5 to 60 minutes. After the addition of Ca(OAc)<sub>2</sub>×H<sub>2</sub>O resulted suspension may be stirred at temperatures from 0 °C to 40 °C from 30 minutes to 2 hours. The desired rosuvastatin calcium may be formed as a solid precipitate, which is conveniently isolated.

**[0028]** Obtained amorphous rosuvastatin calcium of said process is chromatographically pure (over 99.5 % area, mainly over 99.8 % area as measured by HPLC), but may contain various amounts of residual cations, in the case of sodium hydroxide used in said hydrolysis residual amounts of sodium cation. In order to make a conversion process more repeatable in removing most of sodium cation, special care for stirring should be performed. So the precipitation of rosuvastatin calcium salt from the reaction mixture may be executed by stirring said reaction mixture with ultraturrax (Ultra-Turrax® is brand name of IKA Werke GmbH & Co., Staufen, Germany) for dispersion making device with high speed rotation unit) in operation speed from 6000 rpm to 30000 rpm, preferably from 15000 rpm to 25000 rpm, most preferably 16000 rpm to 20000 rpm. The obtained rosuvastatin calcium may also be redigested in fresh water and executing Ultraturax® stirring at the same conditions. In such preferred case content of sodium cation falls in desired rosuvastatin calcium below 0.1 % by weight.

**[0029]** Washing of cationic impurities from the desired rosuvastatin calcium product may be carried out not only in water but also in appropriate solvent / water mixture, preferably tetrahydrofuran / water mixture.

**[0030]** Applying the treatment of rosuvastatin calcium with the mixture of acetone and water a monohydrate of rosuvastatin calcium salt may be prepared. Obtained crystal form of said product is identical to rosuvastatin calcium monohydrate from the prior art as proved by X-ray diffraction pattern (XRD) analysis (see Figure 2). Rosuvastatin calcium monohydrate may be prepared by retreating any form of rosuvastatin calcium in the mixture of acetone and water or prepared by converting other rosuvastatin salts or rosuvastatin acid with calcium source in the mixture of acetone and water.

**[0031]** In the second embodiment of the invention of using amide aprotic solvent, i.e. *N,N*-dimethylacetamide (DMA) in combination with diethylether, and sodium hydroxide in hydrolysis of starting C<sub>1</sub> to C<sub>6</sub> rosuvastatin esters but in the absence of water the amide aprotic solvent is evaporated under the reduced pressure at temperatures from 10 °C to 50 °C. The obtained sodium salt of rosuvastatin may be isolated. The mixture of DMA and diethylether is in the ratio of 1:1 to 3:1 by volume. Hydrolysis may be performed at temperatures from 0 °C to 30 °C and is accomplished in 30 to 90 minutes. Precipitation of the desired rosuvastatin salt may be achieved with additional amounts of ethers, such as diethyl ether (Et<sub>2</sub>O), *tert*-butyl methyl ether (*t*BuMeO), diisopropyl ether (*i*Pr<sub>2</sub>O). In such case after removing of solvents the resulted rosuvastatin salt, preferably rosuvastatin sodium salt is washed and isolated as easy filtrable solid. The term "reduced pressure" generally refers to a pressure of about 10 mbar to about 50 mbar.


**[0032]** Thereafter rosuvastatin sodium salt is dissolved in water and then a source of calcium ions is added. Before adding a source of calcium the aqueous solution of rosuvastatin salt of a base may be optionally washed with a water immiscible organic solvent followed by removing of said solvent. For instance calcium halogenide, preferably calcium chloride, another calcium source, for example calcium nitrate or calcium hydroxide, calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid, preferably calcium palmitate, calcium 2-ethylhexanoate, calcium pivalate or calcium acetate may be used in said conversion. Addition of Ca(OAc)<sub>2</sub>×H<sub>2</sub>O may be performed at temperatures from 0 °C to 40 °C; Ca(OAc)<sub>2</sub>×H<sub>2</sub>O may be added in one portion or dropwise in 5 to 60 minutes. After the addition of Ca(OAc)<sub>2</sub>×H<sub>2</sub>O suspension may be stirred at temperatures between 0 °C to 40 °C from 30 minutes to 2 hours. The obtained amorphous rosuvastatin calcium is formed as a solid precipitate, which is conveniently isolated. Also in this aspect residual amounts of sodium cation containing in rosuvastatin calcium may be reduced with special care on stirring and redigesting, as described above.

**[0033]** Rosuvastatin calcium salt isolated according to any of previously described procedures is in amorphous form. The final product rosuvastatin calcium may be conveniently isolated also as a solvate, preferably as rosuvastatin calcium monohydrate, which may be isolated from the mixture of acetone and water added to rosuvastatin calcium, preferably

from the mixture of acetone and water in the ratio of 2:1 by volume, what is more simple procedure as already known long drawn procedure from the prior art.

**[0034]** Described procedure provides a desired rosuvastatin calcium of high purity where according to the first embodiment of the invention the purity of so produced rosuvastatin calcium exceeds 99.8% area, preferably 99.9% area, while according to the second embodiment the produced rosuvastatin calcium exceeds 99.5 % area, preferably 99.7 % area as measured by HPLC.

**[0035]** The various aspects of the invention are presented in the following scheme 2 and described in detail in following examples:



( $M^+$  denotes alkali metal cation, e.g. sodium cation)

Scheme 2

#### Analytical method

**[0036]** Chromatographic purity is determined by HPLC method by the following method: Equipment: Waters Alliance 2695 separations module, detector PDA 2996, software Empower 5.0; column: Xterra RP 18, 3  $\mu$ m, 150 x 4,6 mm; mobile phase: A: Buffer 10mM  $KH_2PO_4$ , pH=2,5; B: acetonitrile ; temperature: 45  $^{\circ}C$ ; flow rate: 1,2 ml/min; wavelength: 224 and 242 nm; injection volume: 20  $\mu$ l; gradient table:

| t  | % A | % B |
|----|-----|-----|
| 0  | 60  | 40  |
| 15 | 60  | 40  |
| 25 | 50  | 50  |
| 25 | 30  | 70  |
| 40 | 30  | 70  |
| 41 | 60  | 0   |

**[0037]** Powder X-ray diffraction spectra of the sample is recorded on Siemens D-5000,  $CuK\alpha$  radiation, range from  $2^{\circ}$  to  $37^{\circ} 2\theta$ , step  $0.04^{\circ} 2\theta$ , integration time 1 sec, slit V20 in 0.6.

## Example 1

Preparation of rosuvastatin calcium salt via rosuvastatin sodium salt solution

- 5 **[0038]** Rosuvastatin *tert*-butyl ester (60.0 g, 111.6 mmol) is dissolved in 500 mL of a 4:1 mixture of THF / water. The clear solution is warmed to 30 °C and 8.0 M NaOH (15 mL, 120.0 mmol) is added portionwise. The reaction mixture is stirred at 30 °C for 2 hours giving a clear yellow solution. Then THF is removed completely under the reduced pressure (20 mbar) at 40 °C. The remaining aqueous solution is diluted with water to 500 mL and washed with AcOEt (2×200 mL). After separation from the organic layer aqueous phase is distilled under the reduced pressure (20 mbar) at 40 °C
- 10 to completely remove the dissolved AcOEt. The remaining clear solution of sodium rosuvastatinate (440 mL) is diluted with water (60 mL) to 500 mL and warmed to 40 °C. To a vigorously stirring solution of sodium rosuvastatinate is added dropwise  $\text{Ca}(\text{OAc})_2 \times \text{H}_2\text{O}$  (14.8 g, 84.0 mmol in 60 mL of water) over 5 minutes at 40 °C to precipitate rosuvastatin calcium. After the complete addition the suspension is stirred further for 30 minutes at 40 °C. The white precipitate is filtered off. Then a wet white solid is suspended in water (200 mL) and vigorously stirred for 1 hour at 20 °C. The
- 15 undissolved precipitate is collected by filtration, washed with water (200 mL) and dried in vacuum at 40 °C to give 48.5 g (86.8 %) of rosuvastatin calcium salt as white powder (HPLC: 99.87 %).

## Example 2

- 20 **[0039]** Rosuvastatin *tert*-butyl ester (60.0 g, 111.6 mmol) is dissolved in 120 mL of tetrahydrofuran (THF) and 300 mL of water treated 8.0 M NaOH (21 mL) is added portionwise. The reaction mixture is stirred at 50°C for 2 hours. Reaction mixture is allowed to cool to room temperature and washed with 2 x 540 ml of methylcyclohexane.
- [0040]** Aqueous phase is evaporated at 60°C under reduced pressure to 220 ml of total volume to eliminate organic solvents. The residue obtained is rediluted with degassed demi-water to 440 ml of total volume. To the resulting solution
- 25 1.0 g of charcoal is added and the suspension is stirred half an hour. Charcoal is filtered off. One half of the volume of the filtrate (220 ml of total 440 ml) 25.5 ml aqueous solution of calcium chloride (prepared from 10.5 ml 4M calcium chloride and 15 ml demi-water) is added during stirring on ice-bath. The suspension formed is treated vigorously with ultraturax at cca 18000 rpm for 3 minutes. The precipitate is filtered off, suspended anew in 100 ml demi water and treated again with Ultraturax® at 18000 rpm for 3 minutes on ice-bath. The product is separated by filtration, washed
- 30 with 30 ml ice-cold degassed demi-water, collected from the filter and dried 12 hours at 50°C in vacuum desiccator. Yield: 25.05 g of amorphous rosuvastatin calcium (99.75% area, HPLC, 0.085 % Na)
- [0041]** The second aliquot of 220 ml of filtrate is treated on the same way except mechanical stirring instead of ultraturax mixing is performed. Yield 25.11 g (99.72% area, HPLC, 1.55 % Na)

## 35 Example 3

- [0042]** Rosuvastatin *tert*-butyl ester (10.0 g) is dissolved in 20 mL of tetrahydrofuran and 50 ml of water treated 8.0 M NaOH (3.51 mL) is added portionwise. The reaction mixture is stirred at 50°C for 1 hours. One third (26 ml of the total 78 ml) of the resulting solution is washed with 35 ml methylcyclohexane. Methylcyclohexane phase is extracted with 3
- 40 ml demi water. Combined aqueous phases are washed with 20 ml *iso*-propyl acetate. Aqueous phase is then concentrated by evaporation under reduced pressure at 50°C to 15 - 20 ml of total volume. It is cooled on ice-bath and gradually 1.1 ml aqueous solution of 4M calcium chloride is added within a minute during stirring. It is stirred additional 30 minutes on ice-bath and the precipitated product is separated by filtration. The precipitate is washed with 4.0 ml demi water, collected from the filter and dried at room temperature 12 hours in vacuum desiccator.
- 45 Yield: 2.22 g of amorphous rosuvastatin calcium.
- [0043]** Two further aliquots are washed with 20 ml ethyl acetate or 20 ml *tert*-butyl methyl ether respectively with similar yield and quality.

## Example 4

50

Preparation of rosuvastatin sodium salt

- [0044]** Rosuvastatin *tert*-butyl ester (3.0 g, 5.6 mmol) is dissolved in 25 mL of a 4:1 mixture of THF / water. The clear solution is warmed to 30 °C and 8.0 M NaOH (0.75 mL, 6.0 mmol) was added portionwise. The reaction mixture is stirred
- 55 at 30 °C for 2 hours giving a clear yellow solution. Then THF is removed completely under the reduced pressure (20 mbar) at 40 °C. The remaining aqueous solution is diluted with water to 25 mL and washed with AcOEt (2×10 mL). After separation from the organic layer aqueous phase is distilled under the reduced pressure (20 mbar) at 40 °C to completely remove the dissolved AcOEt. The remaining clear solution of sodium rosuvastatinate is diluted with water to 25 mL and

liophylized to afford 2.81 g (100 %) of rosuvastatin sodium salt as white powder.

#### Example 5

- 5 **[0045]** Rosuvastatin *tert*-butyl ester (3.0 g, 5.6 mmol) is dissolved in *N,N*-dimethylacetamide (4 mL) at ambient temperature giving a clear yellow solution. Then NaOH 8.0 M (0.75 mL, 6.0 mmol) is added dropwise to a stirred solution at ambient temperature. The reaction mixture is stirred at ambient temperature for 30 minutes giving a clear yellow solution. Then Et<sub>2</sub>O (50 mL) is added portionwise to the vigorously stirred reaction mixture which becomes immediately turbid and light yellow oil separated from the mixture. After 20 minutes of vigorous stirring oil solidified and fine white precipitate is formed. The suspension is stirred at ambient temperature for 2.5 hours. The white precipitate (sodium rosuvastatinate) is filtered off and washed with Et<sub>2</sub>O (2×20 mL).

#### Example 6

##### 15 Preparation of rosuvastatin calcium salt from isolated rosuvastatin sodium salt

- [0046]** Rosuvastatin sodium as white solid from Example 5 is dissolved in water (30 mL) and solution is filtered to give clear colourless solution. The pH of solution is adjusted to 7 by addition of 1.0 M HCl (0.5 mL). To a vigorously stirring solution of sodium rosuvastatinate is added dropwise Ca(OAc)<sub>2</sub>×H<sub>2</sub>O (0.74 g, 4.2 mmol in 3 mL of water) over 1 minute at ambient temperature to precipitate rosuvastatin calcium. After the complete addition the suspension is stirred further for 45 minutes at ambient temperature. The white precipitate is filtered off, washed with water (2×10 mL) and dried in vacuum at 40 °C to give 2.43 g (87.0 %) of rosuvastatin calcium salt as white powder (HPLC: 99.72 %).

#### Example 7

25

##### Preparation of crystalline rosuvastatin calcium monohydrate salt

- [0047]** To a rosuvastatin calcium salt (2.0 g, 2.0 mmol) is added 10 mL of a 2:1 mixture of acetone / water. The mixture is stirred at ambient temperature for 30 minutes to give a white turbid solution. Then additional 1 mL of a 2:1 mixture of acetone / water is added into the mixture. After 10 minutes of stirring at ambient temperature white solid precipitates abundantly from the mixture. The precipitate is collected by filtration. After drying in vacuum at 40°C 1.67 g (82.0 %) of crystalline rosuvastatin calcium monohydrate salt is obtained. Crystalline form is confirmed by comparing diffractogram (Figure 2) with reference picture from the prior art.

#### 35 Example 8

##### Preparation of solid rosuvastatin free acid

- [0048]** Rosuvastatin *tert*-butyl ester (27.0 g, 50.2 mmol) is dissolved in 225 mL of a 4:1 mixture of THF/water. The clear solution is warmed to 30 °C and 8.0 M NaOH (6.75 mL, 54.0 mmol) is added portionwise. The reaction mixture is stirred at 30 °C for 2 hours giving a clear yellow solution. Then THF is removed completely under the reduced pressure (20 mbar) at 40 °C. The remaining aqueous solution is diluted with water to 225 mL and washed with AcOEt (3×90 mL). To a vigorously stirring solution of sodium rosuvastatinate is added dropwise HCl 37 % (4.2 mL, 50.2 mmol) at ambient temperature. The obtained white emulsion of a free acid is extracted with AcOEt (150 mL). After separation from the organic layer aqueous phase is additionally extracted with AcOEt (2×50 mL). Organic layers are combined and washed with water (3×30 mL). Then AcOEt is removed under reduced pressure (20 mbar) at 40 °C. The residue is dissolved in a minimal amount of acetonitrile (MeCN) and the solvent is rapidly evaporated under reduced pressure (20 mbar) at 40 °C to give 25.48 g of the solid residue of free rosuvastatin acid.

#### 50 Example 9

##### Preparation of crystalline *tert*-octylammonium salt of rosuvastatin

- [0049]** Solid free rosuvastatin acid is then dissolved in acetonitrile (MeCN) (100 mL) to give a clear solution. To a vigorously stirring solution of a rosuvastatin free acid is added dropwise *tert*-octylamine (6.83 g, 50.2 mmol) over 1 minute at ambient temperature. In less than 10 minutes white solid precipitates abundantly from the solution, which cause solidification of the mixture. This solid is then treated with 75 mL of a 1:2 mixture of hexane / MeCN to give a dense suspension. The white precipitate is filtered and dried in vacuum at 40 °C to give 27.6 g of a white powder. This

powder is suspended in hexane (100 mL) and vigorously stirred for 1 hour at ambient temperature. The undissolved precipitate is collected by filtration, washed with hexane (50 mL) and dried in vacuum at 40 °C to give 27.4 g (89.4 %) of rosuvastatin *tert*-octylammonium salt as white crystalline powder.

#### Example 10

**[0050]** 20.0 g of rosuvastatin *tert*-butyl ester is dissolved in the mixture of 40 ml of tetrahydrofuran and 100 ml of water, then 7.0 ml 8M NaOH is added and stirred at 40°C for 1 hour. The resulting solution is washed with 200 ml methylcyclohexane. Methylcyclohexane phase is extracted with 5 ml demi water. Aqueous phases are combined getting 140 ml of total volume of rosuvastatin sodium salt solution.

**[0051]** To this solution 180 ml *iso*-butyl acetate and 5.4 ml 85% orto-phosphoric acid in 21 ml of demi water is added, wherein released free rosuvastatinic acid is extracted in the organic phase and the layers formed are separated. To the organic phase 3.0 g charcoal and 30 g anhydrous magnesium sulfate are added and the resulting suspension is stirred 45 minutes. The following filtration yielded 240 ml of filtrate.

**[0052]** To the filtrate the solution of 84 ml of 0.4 M calcium 2-ethylhexanoate in *iso*-butyl acetate is added. Then, to the reaction mixture 240 ml of n-heptane is gradually added during stirring on the ice-bath. The solid precipitate is filtered off and washed with 120 ml *iso*-butyl acetate/n-heptane mixture (1 : 1). Yield: 19.7 g of amorphous rosuvastatin calcium is collected after drying.

#### Claims

1. A process for producing amorphous rosuvastatin calcium, which comprises:

- a) hydrolysing a C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin with sodium hydroxide in the presence of tetrahydrofuran or with a base in the presence of a mixture of tetrahydrofuran and water, to obtain a solution of rosuvastatin sodium,
- b) converting thus obtained rosuvastatin sodium with a source of calcium to obtain rosuvastatin calcium,
- c) redigesting obtained rosuvastatin calcium in water,
- d) stirring the obtained rosuvastatin calcium, and
- e) isolating amorphous rosuvastatin calcium.

2. The process according to claim 1, wherein stirring is performed with a dispersion making device with high speed rotation unit.

3. The process according to claim 1 or 2, wherein C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin is methyl rosuvastatin or *tert*-butyl rosuvastatin, preferably the C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin is *tert*-butyl rosuvastatin.

4. The process according to claim 4, wherein the ratio of tetrahydrofuran and water is from 5:1 to 1:5 by volume.

5. The process according to claim 4 or 5, wherein the ratio of tetrahydrofuran and water is from 4:1 to 1:3 by volume.

6. The process according to any of previous claims, wherein the source of calcium is selected from the group consisting of calcium chloride, calcium nitrate, calcium hydroxide and calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid.

7. The process according to claim 6 wherein calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid is selected from the group consisting of calcium acetate, calcium acetate monohydrate, calcium palmitate and calcium pivalate.

8. A process for producing amorphous rosuvastatin calcium, which comprises:

- a) hydrolyzing a C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin with sodium hydroxide in *N,N*-dimethylacetamide and diethylether in the absence of water,;
- b) removing the *N,N*-dimethylacetamide and diethylether to obtain a residue of rosuvastatin sodium salt;
- c) optionally washing the obtained residue of rosuvastatin sodium salt and isolating solid rosuvastatin sodium salt,
- d) combining the solid residue of rosuvastatin sodium salt with water to obtain an aqueous solution of rosuvastatin sodium salt;
- e) adding a source of calcium to the resulted solution to precipitate rosuvastatin calcium;
- f) redigesting obtained rosuvastatin calcium in water,

- g) stirring the obtained rosuvastatin calcium, and
- h) isolating amorphous rosuvastatin calcium salt.

9. The process according to claim 8, wherein stirring is performed with a dispersion making device with high speed rotation unit.
10. The process according to claim 2 or 9, wherein the isolated rosuvastatin calcium salt has a sodium cation content below 0.1 % by weight.
11. The process according to any of claims 8 to 10, wherein C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin is methyl rosuvastatin or *tert*-butyl rosuvastatin, preferably the C<sub>1</sub> to C<sub>5</sub> alkyl ester of rosuvastatin is *tert*-butyl rosuvastatin.
12. The process according to claim 8, wherein the ratio of *N,N*-dimethylacetamide and diethyl ether is from 1:1 to 3:1 by volume.
13. The process according to any of claims 8 to 12, wherein the source of calcium is selected from the group consisting of calcium chloride, calcium nitrate, calcium hydroxide and calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid.
14. The process according to claim 13, wherein calcium salt of C<sub>1</sub>-C<sub>20</sub> alkanic acid is selected from the group consisting of calcium acetate, calcium acetate monohydrate, calcium palmitate, calcium 2-ethyl hexanoate and calcium pivalate.
15. The process according to claims 2 and 9, wherein the operation speed of the dispersion making device with high speed rotation unit is from 6000 to 30000 rpm, preferably from 15000 to 25000 rpm, most preferably the operation speed is from 16000 to 20000 rpm.
16. A process for preparing rosuvastatin calcium monohydrate, wherein a 2:1 mixture of acetone and water is added to the amorphous rosuvastatin calcium prepared according to any of previous claims.
17. The process according to any of the previous claims, further comprising manufacturing a pharmaceutical formulation comprising said rosuvastatin calcium for the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
18. A pharmaceutical formulation comprising as active pharmaceutical ingredient rosuvastatin calcium with residual amounts of sodium cation, wherein said rosuvastatin calcium is amorphous rosuvastatin calcium having sodium cation content below 0.1 % by weight.

## Patentansprüche

1. Verfahren zur Herstellung von amorphem Rosuvastatin-Calcium, welches umfasst:
  - a) Hydrolysieren eines C<sub>1</sub> bis C<sub>5</sub>-Alkylesters von Rosuvastatin mit Natriumhydroxid in Gegenwart von Tetrahydrofuran oder mit einer Base in Gegenwart einer Mischung von Tetrahydrofuran und Wasser, um eine Lösung von Rosuvastatin-Natrium zu erhalten,
  - b) Umwandeln des so erhaltenen Rosuvastatin-Natriums mit einer Calciumquelle, um Rosuvastatin-Calcium zu erhalten,
  - c) Wiederverdauen des Rosuvastatin-Calciums in Wasser,
  - d) Rühren des erhaltenen Rosuvastatin-Calciums, und
  - e) Isolieren von amorphem Rosuvastatin-Calcium.
2. Verfahren gemäß Anspruch 1, wobei das Rühren mit einer Vorrichtung zum Herstellen einer Dispersion mit einer Hochgeschwindigkeits-Rotationseinheit ausgeführt wird.
3. Verfahren gemäß Anspruch 1 oder 2, wobei der C<sub>1</sub> bis C<sub>5</sub>-Alkylester von Rosuvastatin Methylrosuvastatin oder *tert*-Butylrosuvastatin ist, vorzugsweise der C<sub>1</sub> bis C<sub>5</sub>-Alkylester von Rosuvastatin *tert*-Butylrosuvastatin ist.
4. Verfahren gemäß Anspruch 4, wobei das Volumenverhältnis von Tetrahydrofuran zu Wasser 5:1 bis 1:5 beträgt.
5. Verfahren gemäß Anspruch 4 oder 5, wobei das Volumenverhältnis von Tetrahydrofuran zu Wasser 4:1 bis 1:3

beträgt.

- 5 6. Verfahren gemäß irgendeinem der vorangehenden Ansprüchen, wobei die Calciumquelle ausgewählt ist aus der Gruppe, die aus Calciumchlorid, Calciumnitrat, Calciumhydroxid und einem Calciumsalz der C<sub>1</sub>-C<sub>20</sub>-Alkansäure besteht.
7. Verfahren gemäß Anspruch 6, wobei das Calciumsalz der C<sub>1</sub>-C<sub>20</sub>-Alkansäure ausgewählt ist aus der Gruppe, die aus Calciumacetat, Calciumacetat-Monohydrat, Calcium-Palmitat und Calciumpivalat besteht.
- 10 8. Verfahren zum Herstellen von amorphem Rosuvastatin-Calcium, welches umfasst:
  - a) Hydrolysieren eines C<sub>1</sub> bis C<sub>5</sub>-Alkylesters von Rosuvastatin mit Natriumhydroxid in N,N-Dimethylacetamid und Dimethylether in Gegenwart von Wasser;
  - 15 b) Entfernen des N,N-Dimethylacetamids und Diethylether, um einen Rückstand von Rosuvastatin-Natriumsalz zu erhalten;
  - c) gegebenenfalls Waschen des erhaltenen Rückstands von Rosuvastatin-Natriumsalz und Isolieren von festem Rosuvastatin-Natriumsalz,
  - d) Vereinigen des festen Rückstandes des Rosuvastatin-Natriumsalzes mit Wasser, um eine wässrige Lösung des Rosuvastatin-Natriumsalzes zu erhalten;
  - 20 e) Einzufügen einer Calciumquelle zur resultierenden Lösung, um Rosuvastatin-Calcium zu präzipitieren;
  - f) Wiederverdauen des erhalten Rosuvastatin-Calciums in Wasser;
  - g) Rühren des erhaltenen Rosuvastatin-Calciums; und
  - h) Isolieren von amorphem Rosuvastatin-Calciumsalz.
- 25 9. Verfahren gemäß Anspruch 8, wobei das Rühren mit einer Vorrichtung zur Herstellung einer Dispersion mit einer Hochgeschwindigkeits-Rotationseinheit ausgeführt wird.
10. Verfahren gemäß Anspruch 2 oder 9, wobei das isolierte Rosuvastatin-Calciumsalz ein Natriumkationengehalt von unter 0,1 Gew.-% hat.
- 30 11. Verfahren gemäß irgendeinem der Ansprüche 8 bis 10, wobei der C<sub>1</sub> bis C<sub>5</sub>-Alkylester von Rosuvastatin Methylrosuvastatin oder *tert*-Butylrosuvastatin ist, vorzugsweise der C<sub>1</sub> bis C<sub>5</sub>-Alkylester von Rosuvastatin *tert*-Butylrosuvastatin ist.
- 35 12. Verfahren gemäß Anspruch 8, wobei das Volumenverhältnis von N,N-Dimethylacetamid zu Diethylether 1:1 bis 3:1 beträgt.
13. Verfahren gemäß irgendeinem der Ansprüche 8 bis 12, wobei die Calciumquelle ausgewählt wird aus der Gruppe, die aus Calciumchlorid, Calciumnitrat, Calciumhydroxid und einem Calciumsalz einer C<sub>1</sub>-C<sub>20</sub>-Alkansäure besteht.
- 40 14. Verfahren gemäß Anspruch 13, wobei das Calciumsalz der C<sub>1</sub>-C<sub>20</sub>-Alkansäure ausgewählt wird aus der Gruppe, die aus Calciumacetat, Calciumacetat-Monohydrat, Calcium-Palmitat, Calcium-2-Ethyl-hexanoat und Calciumpivalat besteht.
- 45 15. Verfahren gemäß Anspruch 2 und 9, wobei die Betriebsgeschwindigkeit der Vorrichtung zur Herstellung einer Dispersion mit einer Hochgeschwindigkeits-Rotationseinheit 6.000 bis 30.000 UPM, vorzugsweise 15.000 bis 25.000 UPM, am meisten bevorzugt die Betriebsgeschwindigkeit 16.000 bis 20.000 UPM beträgt.
- 50 16. Verfahren zur Herstellung von Rosuvastatin-Calciummonohydrat, wobei eine 2:1-Mischung von Aceton und Wasser zu dem amorphem Rosuvastatin-Calcium zugegeben wird, welches gemäß irgendeinem der vorangehenden Ansprüche hergestellt wurde.
17. Verfahren gemäß irgendeinem der vorangehenden Ansprüche, ferner umfassend die Herstellung einer pharmazeutischen Formulierung, die besagtes Rosuvastatin-Calcium umfasst, zur Behandlung der Hyperlipidämie, Hypercholesterolemie und der Atherosklerose.
- 55 18. Pharmazeutische Formulierung, umfassend als aktivem pharmazeutischem Bestandteil Rosuvastatin-Calcium mit Restmengen an Natriumkation, wobei das besagte Rosuvastatin-Calcium amorphes Rosuvastatin-Calcium ist mit

einem Natriumkationengehalt von unter 0,1 Gew.-%.

## Revendications

1. Procédé de production de rosuvastatin calcique amorphe, qui comprend :

- a) l'hydrolyse d'un ester d'alkyle en  $C_1$  à  $C_5$  de rosuvastatin avec de l'hydroxyde de sodium en présence de tétrahydrofurane ou avec une base en présence d'un mélange de tétrahydrofurane et d'eau, pour obtenir une solution de rosuvastatin sodique,
- b) la transformation de la rosuvastatine sodique ainsi obtenue avec une source de calcium pour obtenir de la rosuvastatine calcique,
- c) la redigestion de la rosuvastatine calcique obtenue dans de l'eau,
- d) l'agitation de la rosuvastatine calcique obtenue, et
- e) l'isolement de la rosuvastatine calcique amorphe.

2. Procédé selon la revendication 1, dans lequel l'agitation est effectuée avec un dispositif de réalisation de dispersion à unité de rotation à grande vitesse.

3. Procédé selon la revendication 1 ou 2, dans lequel l'ester d'alkyle en  $C_1$  à  $C_5$  de la rosuvastatine est la rosuvastatin de méthyle ou la rosuvastatine de *tert*-butyle, de préférence l'ester d'alkyle en  $C_1$  à  $C_5$  de la rosuvastatine est la rosuvastatine de *tert*-butyle.

4. Procédé selon la revendication 4, dans lequel le rapport entre tétrahydrofurane et eau est de 5 : 1 à 1 : 5 en volume.

5. Procédé selon la revendication 4 ou 5, dans lequel le rapport entre tétrahydrofurane et eau est de 4 : 1 à 1 : 3 en volume.

6. Procédé selon l'une quelconque des revendications précédentes, dans lequel la source de calcium est choisie dans le groupe constitué par le chlorure de calcium, le nitrate de calcium, l'hydroxyde de calcium et un sel de calcium d'un acide alcanoïque en  $C_1$  à  $C_{20}$ .

7. Procédé selon la revendication 6, dans lequel le sel de calcium d'acide alcanoïque en  $C_1$  à  $C_{20}$  est choisi dans le groupe constitué par l'acétate de calcium, l'acétate de calcium manohydraté, le palmitate de calcium et le pivalate de calcium.

8. Procédé de production de rosuvastatin calcique amorphe, qui comprend :

- a) l'hydrolyse d'un ester d'alkyle en  $C_1$  à  $C_5$  de rosuvastatin avec de l'hydroxyde de sodium dans du *N,N*-diméthylacétamide et du diéthyléther en absence d'eau ;
- b) l'élimination du *N,N*-diméthylacétamide et du diéthyléther pour obtenir un résidu de sel de sodium de rosuvastatin ;
- c) le lavage facultatif du résidu obtenu de sel de sodium de rosuvastatine et l'isolement du sel de sodium de rosuvastatine solide,
- d) la combinaison du résidu solide de sel de sodium de rosuvastatine avec de l'eau pour obtenir une solution aqueuse de sel de sodium de rosuvastatine ;
- e) l'addition d'une source de calcium à la solution résultante pour précipiter la rosuvastatin calcique ;
- f) la redigestion de la rosuvastatine calcique obtenue dans de l'eau,
- g) l'agitation de la rosuvastatine calcique obtenue, et
- h) l'isolement du sel de calcium de rosuvastatin amorphe.

9. Procédé selon la revendication 8, dans lequel l'agitation est effectuée avec un dispositif de réalisation de dispersion à unité de rotation à grande vitesse.

10. Procédé selon la revendication 2 ou 9, dans lequel le sel de calcium de rosuvastatine isolé a une teneur en cations sodium en dessous de 0,1 % en poids.

11. Procédé selon l'une quelconque des revendications 8 à 10, dans lequel l'ester d'alkyle en  $C_1$  à  $C_5$  de la rosuvastatine

est la rosuvastatine de méthyle ou la rosuvastatin de *tert*-butyle, de préférence l'ester d'alkyle en C<sub>1</sub> à C<sub>5</sub> de la rosuvastatine est la rosuvastatine de *tert*-butyle.

12. Procédé selon la revendication 8, dans lequel le rapport entre *N,N*-diméthylacétamide et diéthyléther est de 1 : 1 à 3 : 1 en volume.

13. Procédé selon l'une quelconque des revendications 8 à 12, dans lequel la source de calcium est choisie dans le groupe constitué par le chlorure de calcium, le nitrate de calcium, l'hydroxyde de calcium et un sel de calcium d'un acide alcanoïque en C<sub>1</sub> à C<sub>20</sub>.


14. Procédé selon la revendication 13, dans lequel le sel de calcium d'acide alcanoïque en C<sub>1</sub> à C<sub>20</sub> est choisi dans le groupe constitué par l'acétate de calcium, l'acétate de calcium monohydrate, le palmitate de calcium, le 2-éthylhexanoate de calcium et le pivalate de calcium.

15. Procédé selon les revendications 2 et 9, dans lequel la vitesse de fonctionnement du dispositif de réalisation de dispersion à unité de rotation à grande vitesse est de 6 000 à 30 000 tr/min, de préférence de 15 000 à 25 000 tr/min, de manière préférée entre toutes la vitesse de fonctionnement est de 16 000 à 20 000 tr/min.

16. Procédé de préparation de rosuvastatine calcique monohydratée, dans lequel un mélange à 2 : 1 d'acétone et d'eau est ajouté à la rosuvastatine calcique amorphe préparée selon l'une quelconque des revendications précédentes.

17. Procédé selon l'une quelconque des revendications précédentes, comprenant en outre la fabrication d'une formulation pharmaceutique comprenant ladite rosuvastatine calcique pour le traitement de l'hyperlipidémie, l'hypercholestérolémie et l'athérosclérose.

18. Formulation pharmaceutique comprenant comme ingrédient pharmaceutique actif de la rosuvastatine calcique avec des quantités résiduelles de cations sodium, dans laquelle ladite rosuvastatine calcique est de la rosuvastatin calcique amorphe ayant une teneur en cations sodium en dessous de 0,1 % en poids.



Scheme 1




Figure 1




Figure 2.

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Patent documents cited in the description**

- EP 521471 B [0002]
- WO 2005023778 A [0003]
- WO 2000042024 A [0004]
- WO 2005040134 A [0005]
- WO 0523778 A [0006]

## Eljárás tiszta amorf rosuvasztatin kalcium előállítására

### Szabadalmi igénypontok

1. Eljárás amorf rosuvasztatin kalcium előállítására, melynek során:

- a) egy rosuvasztatin (1-5 szénatomos)-alkilésztert nátriumhidroxiddal tetrahydrofurán jelenlétében vagy egy bázissal tetrahydrofurán és víz elegye jelenlétében hidrolizálunk, rosuvasztatin nátrium előállítására,
- b) az így nyert rosuvasztatin nátriumot egy kalcium-forrással rosuvasztatin kalciummá alakítjuk,
- c) a kapott rosuvasztatin kalciumot vízben újra feltárjuk,
- d) a kapott rosuvasztatin kalciumot keverjük, és
- e) az amorf rosuvasztatin kalciumot izoláljuk.

2. Az 1. igénypont szerinti eljárás, ahol a keverést nagysebességű rotációs egységet tartalmazó, diszperzió előállítására szolgáló készülékben végezzük.

3. Az 1. vagy 2. igénypont szerinti eljárás, ahol a rosuvasztatin (1-5 szénatomos)-alkilészter metil-rosuvasztatin vagy *terc*-butil-rosuvasztatin közül választott, előnyösen a rosuvasztatin (1-5 szénatomos)-alkilészter *terc*-butil rosuvasztatin.

4. A 4. igénypont szerinti eljárás, ahol a tetrahydrofurán és víz térfogataránya 5:1 és 1:5 közötti.

5. A 4. vagy 5. igénypont szerinti eljárás, ahol a tetrahydrofurán és víz térfogataránya 4:1 és 1:3 közötti.

6. Az előző igénypontok bármelyike szerinti eljárás, ahol a kalciumforrás kalciumklorid, kalciumnitrát, kalciumhidroxid és egy (1-20 szénatomos)-alkánsav kalciumsója közül választott.

7. A 6. igénypont szerinti eljárás, ahol az (1-20 szénatomos)-alkánsav kalciumsója kalciumacetát, kalciumacetát monohidrát, kalcium-palmitát és kalcium-pivalát közül választott.

8. Eljárás amorf rosuvasztatin kalcium előállítására, melynek során:

- a) egy rosuvasztatin (1-5 szénatomos)-alkilésztert nátriumhidroxiddal hidrolizálunk *N,N*-dimetilacetamid és dietiléter jelenlétében, víz távollétében;
- b) az *N,N*-dimetilacetamidot és dietilétert eltávolítjuk, egy rosuvasztatin nátriumsó maradék előállítására;
- c) adott esetben a nyert rosuvasztatin nátriumsó maradékot mossuk és a szilárd rosuvasztatin nátriumsót izoláljuk,
- d) a szilárd rosuvasztatin nátriumsó maradékot vízzel keverjük, a rosuvasztatin nátriumsó vizes oldatának előállítására;
- e) a kapott oldathoz kalciumforrást adunk a rosuvasztatin kalcium kicsapására;
- f) a kapott rosuvasztatin kalciumot vízben újra feltárjuk,
- g) a kapott rosuvasztatin kalciumot keverjük, és
- h) az amorf rosuvasztatin kalciumot izoláljuk.

9. A 8. igénypont szerinti eljárás, ahol a keverést nagysebességű rotációs egységet tartalmazó, diszperzió előállítására szolgáló készülékben végezzük.

10. A 2. vagy 9. igénypont szerinti eljárás, ahol az izolált rosuvasztatin kalciumsó nátrium kation tartalma 0.1 tömeg% alatti.

11. A 8-10. igénypontok bármelyike szerinti eljárás, ahol a rosuvasztatin (1-5 szénatomos)-alkilészter metil-rosuvasztatin vagy *tert*-butil-rosuvasztatin közül választott, előnyösen a rosuvasztatin (1-5 szénatomos)-alkilészter *tert*-butil rosuvasztatin.

12. A 8. igénypont szerinti eljárás, ahol a *N,N*-dimetilacetamid és dietiléter térfogataránya 1:1 és 3:1 közötti.

13. A 8-12. igénypontok bármelyike szerinti eljárás, ahol a kalciumforrás kalciumklorid, kalciumnitrát, kalciumhidroxid és egy (1-20 szénatomos)-alkánsav kalciumsója közül választott.

14. A 13. igénypont szerinti eljárás, ahol az (1-20 szénatomos)-alkánsav kalciumsója kalciumacetát, kalciumacetát monohidrát, kalcium-palmitát, kalcium-2-etil-hexanoát és kalcium-pivalát közül választott.

15. A 2. és 9. igénypont szerinti eljárás, ahol a nagysebességű rotációs egységet tartalmazó, diszperzió előállítására szolgáló készülék fordulatszáma 6000 - 30000 rpm, előnyösen 15000 - 25000 rpm, legelőnyösebben 16000 - 20000 rpm.

16. Eljárás rosuvasztatin kalcium monohidrát előállítására, ahol az előző igénypontok bármelyike szerint előállított amorf rosuvasztatin kalciumhoz aceton és víz 2:1 arányú elegyét adjuk.

17. Az előző igénypontok bármelyike szerinti eljárás, melynek során továbbá hyperlipidémia, hypercholesterolemia és atherosclerosis kezelésére szolgáló, rosuvasztatin kalciumot tartalmazó gyógyászati készítményt állítunk elő.

18. Gyógyászati készítmény, mely gyógyászati hatóanyagként maradéknyi mennyiségű nátrium kationt tartalmazó rosuvasztatin kalciumot tartalmaz, ahol a rosuvasztatin kalcium 0.1 tömeg% alatti mennyiségű nátrium kationt tartalmazó amorf rosuvasztatin kalcium.

Uj. Szentpéteri László  
Szakigazgató  
SBGK Szabványügyi Iroda  
H-1067 Budapest, Városház u. 113.  
Telefon: 06-1-460-1699  
Email: szentpeteri@sbgk.hu